Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Significant Increase in Short Interest

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a significant growth in short interest in May. As of May 29th, there was short interest totaling 45,360 shares, a growth of 67.7% from the May 14th total of 27,047 shares. Based on an average trading volume of 165,199 shares, the short-interest ratio is currently 0.3 days. Currently, 1.0% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. bought a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned about 0.66% of Sonoma Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 1.95% of the stock is owned by institutional investors.

Sonoma Pharmaceuticals Price Performance

Shares of SNOA traded up $0.02 during mid-day trading on Monday, reaching $1.11. 18,579 shares of the company’s stock were exchanged, compared to its average volume of 117,515. The stock has a market capitalization of $5.32 million, a PE ratio of -0.54 and a beta of 1.29. The business’s fifty day simple moving average is $1.49 and its 200-day simple moving average is $2.53. Sonoma Pharmaceuticals has a 52-week low of $0.85 and a 52-week high of $6.92.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.